Source: Eur Respir J, 50 (3) 1701376; 10.1183/13993003.01376-2017



Rating:

Share or cite this content

Citations should be made in the following way:
Peter M.A. Calverley. Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic. Eur Respir J, 50 (3) 1701376; 10.1183/13993003.01376-2017

Member's Comments

No comment yet.

Related content which might interest you: Chronic cough: diagnosis, treatment and psychological consequences Source: ISSN=ISSN 1810-6838, ISBN=, page=164 Year: 2006 Defining “stable chronic hypercapnia” in patients with COPD: the physiological perspective Source: Eur Respir J, 55 (2) 1902365; 10.1183/13993003.02365-2019 Year: 2020 Defining “stable chronic hypercapnia” in patients with COPD: the physiological perspective Source: Eur Respir J, 55 (2) 1902172; 10.1183/13993003.02172-2019 Year: 2020 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Chronic respiratory symptoms but normal lung function: substantial disease burden but little evidence to inform practice Source: Eur Respir J, 54 (3) 1901363; 10.1183/13993003.01363-2019 Year: 2019 Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice Source: Eur Respir J 2013; 41: 1252-1256 Year: 2013 Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Bronchodiator therapy in COPD: physiological effects Source: Breathe 2008; 4: 342-344 Year: 2008 Evaluation of adequacy of pharmacological treatment in relation to severity in patients with chronic obstructive pulmonary disease (COPD) and their clinical correlations. Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 A new perspective on concepts of asthma severity, control and optimum treatment Source: Eur Respir J 2009; 33: 704-705 Year: 2009 Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis? Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy Year: 2017 Defining airflow limitation and chronic obstructive pulmonary disease: the role of outcome studies Source: Eur Respir J 2015; 46: 8-10 Year: 2015 The relevance of respiratory muscle dysfunction and novel treatment options in COPD Source: International Congress 2017 – PG18 Targeting the locomotor and respiratory muscles in chronic obstructive pulmonary disease: novel interventional tools and rehabilitation strategies Year: 2017 The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD Source: International Congress 2017 – COPD management Year: 2017 The effect of regional differences on visual arts interpretation in exacerbation and stable periods of chronic airway diseases Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 The role of biomarkers in the management of severe asthma Source: International Congress 2019 – Severe asthma guidelines: update 2019 Year: 2019 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006